The Prognostic Impact of Dose-attenuated R-CHOP Therapy for Elderly Patients with Diffuse Large B-cell Lymphoma

Akira Tanimura,Risen Hirai,Miki Nakamura,Masataka Takeshita,Shotaro Hagiwara,Akiyoshi Miwa

The Prognostic Impact of Dose-attenuated R-CHOP Therapy for Elderly Patients with Diffuse Large B-cell Lymphoma

2018

Akira Tanimura
Risen Hirai
Miki Nakamura
Masataka Takeshita
Shotaro Hagiwara
Akiyoshi Miwa

Objective Although R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) is a standard therapy for diffuse large B-cell lymphoma (DLBCL), the optimal dose for elderly patients remains unclear.

Keywords:

Diffuse large B-cell lymphoma
Internal medicine
CHOP
Cardiology
Medicine
Discontinuation
Diabetes mellitus
Vincristine
Lymphoma
Prednisone
Rituximab
Gastroenterology
Cyclophosphamide

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations